6533b82ffe1ef96bd129599c

RESEARCH PRODUCT

444P PRODIGE 25 (FFCD 11-01)-FOLFA: A randomized phase II trial evaluating aflibercept associated with LV5FU2 regimen as first-line treatment of non-resectable metastatic colorectal cancers

F. Khemissa AkouzJoëlle EgreteauK. Le MalicotVincent BourgeoisNicolas BarriereM. BaconnierJean-louis LegouxDavid MalkaThomas AparicioV. LorgisVeronique Guerin-meyerDavid TougeronValérie BoigeV. Lebrun-lyRoger FarouxCôme Lepage

subject

First line treatmentOncologymedicine.medical_specialtyRegimenOncologybusiness.industryInternal medicinemedicineHematologybusinessAfliberceptmedicine.drughttps://doi.org/10.1016/j.annonc.2020.08.555